A prospective, randomized, multicenter, comparative and open-label study on hepatotoxicity of anastrozole compared with tamoxifen in adjuvant therapy in postmenopausal women with hormone receptor plus early breast cancer

被引：0
|
作者：
Lin, Y. [1 ]
Liu, J. L. [2 ]
Zhang, X. H. [3 ]
Li, L. [4 ]
Hu, R. [5 ]
Liu, J. [6 ]
Deng, Y. C. [7 ]
Chen, D. D. [8 ]
Zhao, Y. B. [9 ]
Wang, S. M. [1 ]
机构：
[1] Sun Yat Sen Univ, Affiliated Hosp 1, Guangzhou 510275, Guangdong, Peoples R China
[2] Guangxi Tumour Inst & Hosp, Nanning, Peoples R China
[3] Wenzhou Med Coll, Affiliated Hosp 1, Wenzhou, Peoples R China
[4] Dalian Med Univ, Affiliated Hosp 1, Dalian, Peoples R China
[5] Sichuan Canc Hosp, Chengdu, Peoples R China
[6] Fujian Prov Tumor Hosp, Fuzhou, Peoples R China
[7] Zhejiang Univ, Affiliated Hosp 2, Coll Med, Hangzhou 310003, Zhejiang, Peoples R China
[8] Yunnan Tumor Hosp, Kunming, Peoples R China
[9] Sichuan Univ, West China Hosp, Chengdu 610064, Peoples R China
来源：
EUROPEAN JOURNAL OF CANCER | 2013年 / 49卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2067
引用
收藏
页码：S466 / S466
页数：1
相关论文
共 50 条
  • [1] A prospective, randomized study on hepatotoxicity of anastrozole compared with tamoxifen in women with breast cancer
    Lin, Ying
    Liu, Jianlun
    Zhang, Xiaohua
    Li, Li
    Hu, Rui
    Liu, Jian
    Deng, Yongchuan
    Chen, Dedian
    Zhao, Yangbing
    Sun, Shengrong
    Ma, Rong
    Zhao, Ying
    Liu, Jinping
    Zhang, Yang
    Wang, Xijing
    Li, Yafen
    He, Pingqing
    Li, Enxiao
    Xu, Zheli
    Wu, Yaqun
    Tong, Zhongsheng
    Wang, Xiaojia
    Huang, Tao
    Liang, Zhongxiao
    Wang, Shui
    Su, Fengxi
    Lu, Yunfei
    Zhang, Helong
    Feng, Guosheng
    Wang, Shenming
    [J]. CANCER SCIENCE, 2014, 105 (09): : 1182 - 1188
  • [2] Fulvestrant plus anastrozole as neoadjuvant therapy in postmenopausal women with hormone receptor positive early breast cancer
    Khan, Q. J.
    Barr, J. A.
    Britt, A. S.
    Kimler, B. F.
    Connor, C. S.
    McGinness, M.
    Mammen, J. M. V.
    Wagner, J. L.
    Amin, A.
    Springer, M.
    Baccaray, S.
    Fabian, C. J.
    Sing, A. P.
    Sharma, P.
    [J]. CANCER RESEARCH, 2016, 76
  • [3] FACT: An Open-Label Randomized Phase III Study of Fulvestrant and Anastrozole in Combination Compared With Anastrozole Alone As First-Line Therapy for Patients With Receptor-Positive Postmenopausal Breast Cancer
    Bergh, Jonas
    Jonsson, Per-Ebbe
    Lidbrink, Elisabet Kerstin
    Trudeau, Maureen
    Eiermann, Wolfgang
    Brattstrom, Daniel
    Lindemann, Justin P. O.
    Wiklund, Fredrik
    Henriksson, Roger
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (16) : 1919 - 1925
  • [4] 'Arimidex' (anastrozole) versus tamoxifen as adjuvant therapy in postmenopausal women with early breast cancer-efficacy overview
    Buzdar, AU
    [J]. JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY, 2003, 86 (3-5): : 399 - 403
  • [5] Evaluation of endometrial thickness in hormone receptor positive early stage breast cancer postmenopausal women switching from adjuvant tamoxifen treatment to anastrozole
    Menada, Mario Valenzano
    Costantini, Sergio
    Moioli, Melita
    Bogliolo, Stefano
    Papadia, Andrea
    Ferrero, Simone
    Dugnani, Maria Cristina
    [J]. BREAST, 2008, 17 (06): : 631 - 636
  • [6] Postoperative Adjuvant Anastrozole for 10 or 5 Years in Patients With Hormone Receptor-Positive Breast Cancer: AERAS, a Randomized Multicenter Open-Label Phase III Trial
    Iwase, Takuji
    Saji, Shigehira
    Iijima, Kotaro
    Higaki, Kenji
    Ohtani, Shoichiro
    Sato, Yasuyuki
    Hozumi, Yasuo
    Hasegawa, Yoshie
    Yanagita, Yasuhiro
    Takei, Hiroyuki
    Tanaka, Maki
    Masuoka, Hideji
    Tanabe, Masahiko
    Egawa, Chiyomi
    Komoike, Yoshifumi
    Nakamura, Toshitaka
    Ohtsu, Hiroshi
    Mukai, Hirofumi
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (18) : 3329 - +
  • [7] Cost-effectiveness of anastrozole versus tamoxifen as adjuvant therapy for postmenopausal women with early hormone-receptor positive breast cancer - an evaluation of the ATAC-trial.
    Lundkvist, J.
    Paulsson, T.
    Borgstrom, F.
    Kasteng, F.
    Sobocki, P.
    Lidgren, M.
    Henriksson, R.
    [J]. BREAST CANCER RESEARCH AND TREATMENT, 2006, 100 : S229 - S229
  • [8] Pharmacoeconomic aspects of adjuvant early breast cancer treatment in postmenopausal women with anastrozole or tamoxifen: a Slovenian perspective
    Piskur, R.
    Sonc, M.
    Cufer, T.
    Borstnar, S.
    Mrhar, A.
    [J]. EJC SUPPLEMENTS, 2004, 2 (03): : 75 - 75
  • [9] A MULTICENTER PROSPECTIVE RANDOMIZED CONTROLLED TRIAL OF ADJUVANT NOLVADEX (TAMOXIFEN) THERAPY IN EARLY BREAST-CANCER
    WILSON, AJ
    BAUM, M
    BRINKLEY, D
    DOSSETT, JA
    MCPHERSON, K
    RUBENS, RD
    STOLL, BA
    SMIDDY, FG
    PATTERSON, J
    BARNES, DM
    HOLDAWAY, IM
    KING, R
    LEAKE, R
    NICHOLSON, R
    LEA, J
    ELLIS, S
    RICHARDS, D
    [J]. BRITISH JOURNAL OF SURGERY, 1982, 69 (11) : 688 - 688
  • [10] Efficacy of Pre-operative Arimidex (anastrozole) compared with Tamoxifen (PROACT) as neoadjuvant therapy in postmenopausal women with hormone receptor-positive breast cancer
    Cataliotti, L.
    Buzdar, A.
    Noguchi, S.
    Bines, J.
    [J]. EJC SUPPLEMENTS, 2004, 2 (03): : 69 - 69
12345